Breaking News

AGC Biologics Seattle Facility Achieves Regulatory and Operational Milestones

Positions Seattle site as a premier destination for mammalian and microbial biologic production in the Pacific Northwest life sciences hub.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics’ Seattle manufacturing facility has reached significant milestones in 2025, reinforcing its role as a key player in the biopharmaceutical industry. The site successfully completed a routine U.S. Food and Drug Administration (FDA) surveillance inspection in April 2025, following a 2024 Pre-License Inspection that led to FDA approval for commercial production of three Biologics License Applications. The facility also secured regulatory product approvals in ten countries, including...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters